Dimerix (DXB.AX) Stock Price

Dimerix Price

ASX·CLOSED
0.24AUD-0.02 (-6.06 %)
Market closed

Over the last 19 years Dimerix grew revenue by 26.3% annually, reaching 5.91 M AUD. For Dimerix, the net margin of -224.1% is up versus -424,780.0% a few years ago. The stock trades about 45% above its 52-week low.

Dimerix stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Dimerix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Dimerix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Dimerix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Dimerix Stock Price History
DateDimerix Price
7/10/20260.24 AUD
7/9/20260.25 AUD
7/8/20260.24 AUD
7/7/20260.25 AUD
7/6/20260.26 AUD
7/3/20260.23 AUD
7/2/20260.25 AUD
7/1/20260.21 AUD
6/30/20260.20 AUD
6/29/20260.21 AUD
6/26/20260.20 AUD
6/25/20260.20 AUD
6/24/20260.19 AUD
6/23/20260.20 AUD
6/22/20260.22 AUD
6/19/20260.22 AUD
6/18/20260.21 AUD
6/17/20260.19 AUD
6/16/20260.20 AUD
6/15/20260.17 AUD
6/12/20260.17 AUD
6/11/20260.17 AUD
6/10/20260.17 AUD
6/9/20260.17 AUD
6/5/20260.17 AUD
6/4/20260.17 AUD
6/3/20260.17 AUD
6/2/20260.17 AUD
6/1/20260.19 AUD
5/29/20260.19 AUD
5/28/20260.17 AUD
5/27/20260.19 AUD
5/26/20260.19 AUD
5/25/20260.20 AUD
5/22/20260.20 AUD
5/21/20260.20 AUD
5/20/20260.20 AUD
5/19/20260.20 AUD
5/18/20260.21 AUD
5/15/20260.22 AUD
5/14/20260.22 AUD
5/13/20260.22 AUD
5/12/20260.21 AUD
5/11/20260.20 AUD
5/8/20260.22 AUD
5/7/20260.20 AUD
5/6/20260.20 AUD
5/5/20260.20 AUD
5/4/20260.23 AUD
5/1/20260.22 AUD
4/30/20260.23 AUD
4/29/20260.22 AUD
4/28/20260.24 AUD
4/27/20260.39 AUD
4/24/20260.38 AUD
4/23/20260.38 AUD
4/22/20260.39 AUD
4/21/20260.38 AUD
4/20/20260.38 AUD
4/17/20260.40 AUD
4/16/20260.41 AUD
4/15/20260.41 AUD
4/14/20260.38 AUD
4/13/20260.33 AUD
4/10/20260.34 AUD
4/9/20260.36 AUD
4/8/20260.35 AUD
4/7/20260.32 AUD
4/2/20260.32 AUD
4/1/20260.31 AUD
3/31/20260.30 AUD
3/30/20260.29 AUD
3/27/20260.32 AUD
3/26/20260.32 AUD
3/25/20260.32 AUD
3/24/20260.32 AUD
3/23/20260.32 AUD
3/20/20260.32 AUD
3/19/20260.33 AUD
3/18/20260.37 AUD
3/17/20260.38 AUD
3/16/20260.35 AUD
3/13/20260.35 AUD
3/12/20260.37 AUD
3/11/20260.36 AUD
3/10/20260.38 AUD
3/9/20260.38 AUD
3/6/20260.41 AUD
3/5/20260.41 AUD
3/4/20260.40 AUD
3/3/20260.41 AUD
3/2/20260.44 AUD
2/27/20260.47 AUD
2/26/20260.46 AUD
2/25/20260.44 AUD
2/24/20260.44 AUD
2/23/20260.45 AUD
2/20/20260.47 AUD
2/19/20260.47 AUD
2/18/20260.47 AUD
2/17/20260.48 AUD
2/16/20260.50 AUD
2/13/20260.47 AUD
2/12/20260.50 AUD
2/11/20260.52 AUD
2/10/20260.53 AUD
2/9/20260.50 AUD
2/6/20260.49 AUD
2/5/20260.51 AUD
2/4/20260.52 AUD
2/3/20260.51 AUD
2/2/20260.51 AUD
1/30/20260.50 AUD
1/29/20260.51 AUD
1/28/20260.52 AUD
1/27/20260.52 AUD
1/23/20260.52 AUD
1/22/20260.52 AUD
1/21/20260.53 AUD
1/20/20260.52 AUD
1/19/20260.53 AUD
1/16/20260.54 AUD
1/15/20260.55 AUD
1/14/20260.56 AUD
1/13/20260.54 AUD
1/12/20260.55 AUD
1/9/20260.54 AUD
1/8/20260.54 AUD
1/7/20260.56 AUD
1/6/20260.54 AUD
1/5/20260.56 AUD
1/2/20260.55 AUD
12/31/20250.55 AUD
12/30/20250.56 AUD
12/29/20250.56 AUD
12/24/20250.54 AUD
12/23/20250.63 AUD
12/22/20250.61 AUD
12/19/20250.56 AUD
12/18/20250.56 AUD
12/17/20250.57 AUD
12/16/20250.57 AUD
12/15/20250.61 AUD
12/12/20250.60 AUD
12/11/20250.62 AUD
12/10/20250.58 AUD
12/9/20250.57 AUD
12/8/20250.56 AUD
12/5/20250.56 AUD
12/4/20250.53 AUD
12/3/20250.53 AUD
12/2/20250.50 AUD
12/1/20250.50 AUD
11/28/20250.52 AUD
11/27/20250.50 AUD
11/26/20250.48 AUD
11/25/20250.47 AUD
11/24/20250.46 AUD
11/21/20250.46 AUD
11/20/20250.47 AUD
11/19/20250.47 AUD
11/18/20250.46 AUD
11/17/20250.47 AUD
11/14/20250.48 AUD
11/13/20250.50 AUD
11/12/20250.50 AUD
11/11/20250.50 AUD
11/10/20250.48 AUD
11/7/20250.47 AUD
11/6/20250.50 AUD
11/5/20250.47 AUD
11/4/20250.49 AUD
11/3/20250.50 AUD
10/31/20250.51 AUD
10/30/20250.49 AUD
10/29/20250.50 AUD
10/28/20250.50 AUD
10/27/20250.51 AUD
10/24/20250.51 AUD
10/23/20250.52 AUD
10/22/20250.52 AUD
10/21/20250.55 AUD
10/20/20250.51 AUD
10/17/20250.51 AUD
10/16/20250.53 AUD
10/15/20250.52 AUD
10/14/20250.52 AUD
10/13/20250.52 AUD
10/10/20250.55 AUD
10/9/20250.55 AUD
10/8/20250.56 AUD
10/7/20250.52 AUD
10/6/20250.52 AUD
10/3/20250.55 AUD
10/2/20250.54 AUD
10/1/20250.54 AUD
9/30/20250.52 AUD
9/29/20250.51 AUD
9/26/20250.51 AUD
9/25/20250.52 AUD
9/24/20250.50 AUD
9/23/20250.51 AUD
9/22/20250.51 AUD
9/19/20250.51 AUD
9/18/20250.54 AUD
9/17/20250.52 AUD
9/16/20250.53 AUD
9/15/20250.54 AUD
9/12/20250.51 AUD
9/11/20250.47 AUD
9/10/20250.47 AUD
9/9/20250.49 AUD
9/8/20250.51 AUD
9/5/20250.47 AUD
9/4/20250.48 AUD
9/3/20250.47 AUD
9/2/20250.45 AUD
9/1/20250.45 AUD
8/29/20250.45 AUD
8/28/20250.44 AUD
8/27/20250.47 AUD
8/26/20250.47 AUD
8/25/20250.47 AUD
8/22/20250.46 AUD
8/21/20250.47 AUD
8/20/20250.47 AUD
8/19/20250.47 AUD
8/18/20250.46 AUD
8/15/20250.47 AUD
8/14/20250.47 AUD
8/13/20250.49 AUD
8/12/20250.49 AUD
8/11/20250.49 AUD
8/8/20250.52 AUD
8/7/20250.51 AUD
8/6/20250.49 AUD
8/5/20250.47 AUD
8/4/20250.47 AUD
8/1/20250.48 AUD
7/31/20250.47 AUD
7/30/20250.47 AUD
7/29/20250.51 AUD
7/28/20250.55 AUD
7/25/20250.56 AUD
7/24/20250.55 AUD
7/23/20250.54 AUD
7/22/20250.54 AUD
7/21/20250.53 AUD
7/18/20250.55 AUD
7/17/20250.55 AUD
7/16/20250.56 AUD
7/15/20250.56 AUD
7/14/20250.54 AUD
Access this data via the Eulerpool API
Get Free API Key

Dimerix Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
20,200.00 AUD
-3.32 M AUD
-3.32 M AUD
Jan 1, 2019
18,100.00 AUD
-2.89 M AUD
-2.89 M AUD
Jan 1, 2020
2,700.00 AUD
-4.49 M AUD
-4.49 M AUD
Jan 1, 2021
1,500.00 AUD
-6.32 M AUD
-6.37 M AUD
Jan 1, 2022
2,400.00 AUD
-10.44 M AUD
-10.49 M AUD
Jan 1, 2023
36,800.00 AUD
-13.75 M AUD
-13.80 M AUD
Jan 1, 2024
583,500.00 AUD
-16.92 M AUD
-17.08 M AUD
Jan 1, 2025
5.91 M AUD
-31.01 M AUD
-13.25 M AUD

Dimerix Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 10:14 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
–––––––––––––––5.00
––––––––––––––––
–––––––––––––––20.00
1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
––––––-5.00-1.00-3.00-2.00-4.00-6.00-10.00-13.00-17.00-13.00
–––––––-80.00200.00-33.33100.0050.0066.6730.0030.77-23.53
10.2210.2210.2213.2917.3820.9171.4085.24115.42158.61174.56201.38299.52325.53452.91560.42
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Dimerix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Dimerix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Dimerix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Dimerix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Dimerix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Dimerix stock margins

The Dimerix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dimerix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dimerix.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
60.00 %
-16,434.16 %
-16,434.16 %
Jan 1, 2019
60.00 %
-15,945.86 %
-15,945.86 %
Jan 1, 2020
60.00 %
-166,451.86 %
-166,451.86 %
Jan 1, 2021
60.00 %
-421,466.65 %
-424,780.00 %
Jan 1, 2022
60.00 %
-435,162.50 %
-437,108.30 %
Jan 1, 2023
60.00 %
-37,352.17 %
-37,507.61 %
Jan 1, 2024
60.00 %
-2,900.17 %
-2,926.32 %
Jan 1, 2025
60.00 %
-524.31 %
-224.08 %

Dimerix Stock Revenue, EBIT, Earnings per Share

The Dimerix earnings per share therefore indicates how much revenue Dimerix has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 AUD
-0.03 AUD
-0.03 AUD
Jan 1, 2019
0.00 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2020
0.00 AUD
-0.03 AUD
-0.03 AUD
Jan 1, 2021
0.00 AUD
-0.03 AUD
-0.03 AUD
Jan 1, 2022
0.00 AUD
-0.03 AUD
-0.04 AUD
Jan 1, 2023
0.00 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2024
0.00 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2025
0.01 AUD
-0.06 AUD
-0.02 AUD

Dimerix business model & stock analysis

Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future.

Dimerix SWOT Analysis

Strengths

Dimerix Ltd possesses several strengths that contribute to its success:

  • Strong intellectual property portfolio, providing a competitive advantage in the market.
  • Advanced technology and expertise in the development of innovative therapeutics.
  • Diverse and experienced management team with a track record of successful commercialization.
  • Strategic partnerships with leading pharmaceutical companies, enhancing research and development opportunities.
  • Strong financial position and access to capital, facilitating future growth and expansion.

Weaknesses

Despite its strengths, Dimerix Ltd faces certain weaknesses that need to be addressed:

  • Relatively small size and limited resources compared to established competitors.
  • Dependency on key partnerships, creating the risk of potential disruptions or conflicts.
  • Limited market presence and brand recognition, making it challenging to attract customers and investors.

Opportunities

Dimerix Ltd can capitalize on various opportunities to drive growth and achieve success:

  • Expanding market demand for novel therapeutics, particularly in the field of [specific therapeutic area].
  • Potential collaborations with academic institutions and research organizations to access new technologies and ideas.
  • Growing interest from investors in the biotech sector, providing potential funding opportunities.

Threats

Dimerix Ltd should be aware of the following threats that may hinder its progress:

  • Intense competition from both established pharmaceutical companies and emerging biotech firms.
  • Regulatory challenges and strict approval processes for new therapeutics.
  • Potential disruptions in the supply chain or manufacturing processes, impacting product availability.
  • Market volatility and economic uncertainties, affecting investor confidence and funding availability.

Dimerix Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Dimerix historical P/E ratio, EBIT multiple, and P/S ratio

Dimerix annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Dimerix shares outstanding

The number of shares of Dimerix was 560.42 M in 2025. This indicates how many shares Dimerix is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
115.42 M Stocks
Jan 1, 2019
158.61 M Stocks
Jan 1, 2020
174.56 M Stocks
Jan 1, 2021
201.38 M Stocks
Jan 1, 2022
299.52 M Stocks
Jan 1, 2023
325.53 M Stocks
Jan 1, 2024
452.91 M Stocks
Jan 1, 2025
560.42 M Stocks

Dimerix stock splits

In Dimerix's history, there have been no stock splits.

Dimerix Dividend History

2 years of dividend payments

YearAnnual DividendYoY ChangePayments
19990.03AUD↓ 28.6%2×
19980.04AUD—1×
Price targets and forecasts for Dimerix are not yet available.

Dimerix shareholder structure

% Name
7.93425%
Meurs (Peter Fletcher)
Meurs (Peter Fletcher)
7.63596%
Skiptan Pty. Ltd.
Skiptan Pty. Ltd.
1.79879%
Precision Opportunities Fund Ltd.
Precision Opportunities Fund Ltd.
1.30562%
Bavaria Bay Pty. Ltd.
Bavaria Bay Pty. Ltd.
1.21337%
Pengana Capital Group Limited
Pengana Capital Group Limited
0.97872%
De Ravin (Richard Stanley)
De Ravin (Richard Stanley)

Dimerix Executives and Management Board

NW

Dr. Nina Webster

Chief Executive Officer, Managing Director, Director · since 2018

Compensation407,849.00 AUD
HA

Mr. Hugh Alsop

Non-Executive Director

Compensation60,000.00 AUD
SP

Dr. Sonia Poli

(57)

Non-Executive Director

Compensation60,000.00 AUD
MD

Mr. Mark Diamond

Non-Executive Chairman of the Board

HG

Mr. Hamish George

Chief Financial Officer, Company Secretary

Dimerix Supply Chain

Dimerix Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
IQVIA Holdings
Supplier
-0.06
0.54
0.72
0.67
-0.40

Frequently asked questions about Dimerix

Dimerix Ltd is an Australian-based biopharmaceutical company specializing in the development of innovative therapies. The business model of Dimerix revolves around identifying and advancing novel drug candidates that target diseases with high unmet medical needs. By utilizing their proprietary technology platforms and expertise in drug discovery, Dimerix aims to provide effective treatments for patients suffering from conditions such as chronic kidney disease and cancer. Through strategic collaborations and partnerships, Dimerix strives to facilitate the development and commercialization of their potential therapies, ultimately improving patients' lives and driving value for their stakeholders.

All fundamentals and in-depth analysis of Dimerix

Our stock analysis for Dimerix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dimerix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Dimerix Stock
Dimerix Revenue→
Dimerix Stock
Dimerix Net Income→
Dimerix Stock
Dimerix P/E→
Dimerix Stock
Dimerix P/S→
Dimerix Stock
Dimerix EBIT→
Dimerix Stock
Dimerix Dividend→
Dimerix Stock
Dimerix Directors Dealings→
Dimerix Stock
Dimerix Stocks→
Dimerix Stock
Dimerix Market capitalization→
Dimerix Stock
Dimerix Debt→
Dimerix Stock
Dimerix Liabilities→
Dimerix Stock
Dimerix Equity→
Dimerix Stock
Dimerix AAQS→
Dimerix Stock
Dimerix Employees→
Dimerix Stock
Dimerix ROE→
Dimerix Stock
Dimerix ROA→
Dimerix Stock
Dimerix ROCE→
Dimerix Stock
Dimerix News→
Dimerix Stock
Dimerix Analyst Price Targets→

Health Stocks

DioDiastika Biotekindo Tbk PTDipna PharmachemDiaSorin SpADirui Industrial CoDianthus TherapeuticsDisc MedicineDian Diagnostics Group CoDishman Carbogen AmcisDiamyd MedicalDivi's LaboratoriesDiamond Biotechnology CoAll Stocks A–Z →